ArticleHuman vaccines & immunotherapeutics2026
The use of the HPV vaccine in a group of primarily unvaccinated HPV-positive patients.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman papillomavirus (HPV) infection remains the most prevalent sexually transmitted viral infection worldwide and a major etiologic factor for cervical and other anogenital cancers. HPV-related precancerous lesions continue to represent a substantial clinical and epidemiological burden.
objectiveWe aim to assess the effects of nine-valent HPV vaccination on viral clearance, genotype distribution, and lesion regression among HPV-positive women who were unvaccinated in childhood.
methodsWe enrolled 461 women between January 2020 and August 2025 to the study who presented with abnormal cytology, positive hrHPV tests, or abnormal colposcopic findings. Participants underwent LBC, HPV genotyping, colposcopy, and biopsy or LEEP when indicated. The vaccinated cohort (n = 351) received the Gardasil®9 series (0-2-6 months), while 110 women served as unvaccinated controls. Statistical analyses were performed using R software (v4.4.2) with a significance threshold of α = 0.05.
resultsFollowing vaccination, HPV positivity for any genotype was significantly lower in the vaccinated group than in the control group (29.3% vs 56.4%,
conclusionsNine-valent HPV vaccination significantly enhanced viral clearance and reduced persistence and recurrence of high-grade squamous intraepithelial lesions (HSIL) among previously unvaccinated HPV-positive women. These findings support extending vaccination recommendations to adult HPV-positive patients as an adjunctive strategy to surgical and cytologic management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.